Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Bavituximab Plus Carbo and Pemetrexed in Chemo-Naive Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Subjects

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
Peregrine Pharmaceuticals
Information provided by (Responsible Party):
UNC Lineberger Comprehensive Cancer Center
ClinicalTrials.gov Identifier:
NCT01323062
First received: March 8, 2011
Last updated: May 9, 2016
Last verified: May 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: May 2017
  Primary Completion Date: April 2014 (Final data collection date for primary outcome measure)